Clinical trial · Interventional
Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors
A Phase I Trial Of Gemcitabine Followed By Flavopiridol In Patients With Solid Tumors
NCT00007917CI-TRIAL-00009593completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase I trial to study the effectiveness of gemcitabine plus flavopiridol in treating patients who have advanced solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| alvocidib | Drug | Alvocidib | ALIAS |
| gemcitabine hydrochloride | Drug | Gemcitabine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm I
- description
- Patients receive gemcitabine IV over 1-2.5 hours on days 1 and 8 and flavopiridol IV continuously over 24 hours on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- interventionNames
- Drug: alvocidib
- Drug: gemcitabine hydrochloride
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven solid tumor for which gemcitabine is a treatment option or for which no effective therapy exists * Previously untreated disease allowed * No large and potentially symptomatic pericardial effusion or undrained pleural effusion (with or without pleurodesis) * No CNS metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * At least 12 weeks Hematopoietic: * Absolute neutrophil count at least 2,000/mm3 * Platelet count at least 100,000/mm3 * No prior thrombotic events Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 2 times upper limit of normal Renal: * Creatinine no greater than 1.5 mg/dL Cardiovascular: * No clinically significant cardiac disease * No prior deep venous thrombus * No prior arterial vascular event * No prior myocardial infarction * No unstable angina * No prior transient ischemic attack or cerebrovascular accident * No cardiac arrhythmias that could be related to cardiac ischemia Pulmonary: * No clinically significant pulmonary disease * No history of pulmonary embolism Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No active infection * No severe malnutrition or intractable emesis * No chronic diarrheal disease within the past 6 months PRIOR CONCURRENT THERAPY: Chemotherapy: * No more than 1 prior chemotherapy regimen * At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * Prior gemcitabine or flavopiridol allowed * No other concurrent chemotherapy Radiotherapy: * At least 3 weeks since prior radiotherapy and recovered * No prior radiotherapy to more than 50% of bone marrow * No concurrent radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.